Baird Maintains Outperform on New Relic, Raises Price Target to $90

Baird analyst Rob Oliver maintains New Relic (NYSE:NEWR) with a Outperform and raises the price target from $75 to $90.

byBenzinga Newsdesk

February 8, 2023

1 minute read

Baird analyst Rob Oliver maintains New Relic (NYSE:NEWR) with a Outperform and raises the price target from $75 to $90.

Cathie Wood Loads Up $2.7M In Tesla On Day Shares Crash 11.4% — Also Adds This Bitcoin Related Stock

By Bhavik Nair

Today, 10:29 AM

On a day Tesla Inc (NASDAQ: TSLA) stock dropped to over two-year lows, Cathie Wood’s ARK Investment Management took the opportunity to load up on the EV maker’s shares, displaying its

$DOGE

Piper Sandler Maintains Neutral on Squarespace, Lowers Price Target to $50

By Benzinga Newsdesk

Today, 10:29 AM

Piper Sandler analyst Brent Bracelin maintains Squarespace (NYSE:SQSP) with a Neutral and lowers the price target from $62 to $50.

SQSP

FDA
News

Marinus Pharma Reports Received FDA Orphan Drug Designation for Ganaxolone In Tuberous Sclerosis Complex Following Topline Phase 2 Open-Label Results

By Benzinga Newsdesk

Today, 10:29 AM

Primary endpoint showed a median 16.6% reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23) Secondary endpoint of 50% responder rate at 30.4%, consistent with

MRNS

Elon Musk Says Tesla Giga Shanghai Returning ‘With A Vengeance’ After COVID-19 Halts, Sees Record Q2 Output

By Rachit Vats

Today, 10:29 AM

Tesla Inc's (NASDAQ: TSLA) Giga Shanghai could spring a production surprise in the current quarter as the key plant returns to production after weeks of shutdowns due to COVID-19 curbs in China.

TSLA

Baird Maintains Outperform on New Relic, Raises Price Target to $90

Related Posts

Cathie Wood Loads Up $2.7M In Tesla On Day Shares Crash 11.4% — Also Adds This Bitcoin Related Stock

Piper Sandler Maintains Neutral on Squarespace, Lowers Price Target to $50

Marinus Pharma Reports Received FDA Orphan Drug Designation for Ganaxolone In Tuberous Sclerosis Complex Following Topline Phase 2 Open-Label Results

Elon Musk Says Tesla Giga Shanghai Returning ‘With A Vengeance’ After COVID-19 Halts, Sees Record Q2 Output